Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds

Abstract

Our study showed that SU monotherapy resulted in satisfactory glycemic control in most of the patients with NDM whose genetic defects are heterogeneous. The usage of SU may be considered as first-line therapy for patients with NDM in developing countries where effective genetic screening is not established.

Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: Experience from China

“…Sulfonylurea therapy may be an effective first-line treatment for patients with NDM. 14 We report here our experience with a good sulfonylurea response rate of 69% (11/16) in NDM patients who were switched from insulin to sulfonylurea therapy in early infancy (4 months or less) before genetic testing results were available. These patients were able to maintain good glycemic control, with fewer hypoglycemic episodes compared with insulin therapy, with a maintenance dose of sulfonylurea of <0.5 mg/kg/d.…”

“…Sulfonylurea therapy may be an effective first‐line treatment for patients with NDM . We report here our experience with a good sulfonylurea response rate of 69% (11/16) in NDM patients who were switched from insulin to sulfonylurea therapy in early infancy (4 months or less) before genetic testing results were available.…”

Successful off-label sulfonylurea treatment of neonatal diabetes mellitus due to chromosome 6 abnormalities

“…Of the 11 patients, 7 achieved good glycemic control with SU therapy alone, although one required the addition of insulin after 11 years. The other 4 patients required combination therapy with a SU and 1 or 2 other oral antidiabetic agents; none required insulin . The first case of successful SU therapy of TNDM was reported in 2009 …”

“…The number of patients with 6q24‐related TNDM is still too small to determine whether the effect of SU therapy varies across genotypes. Diabetes with all 3 6q24 abnormalities has been reported to respond to SU therapy . Nevertheless, a larger sample size is needed to assess this issue.…”

Molecular and clinical features of KATP -channel neonatal diabetes mellitus in Japan

“…[13][14][15][16][17][18] Although the data on genotype-phenotype correlation and the effects of sulfonylurea are accumulating, there have been few reports on the Asian population, most of which being single case reports. [19][20][21][22][23][24][25][26][27][28] In this study, we accumulated the largest number of K ATP -channel NDM cases in Japanese patients and analyzed their genotype-phenotype correlations and their response to sulfonylurea.…”